These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 1808341)

  • 21. [The trend in the development of the active vitamin D3 and its analogues].
    Miwa N; Akiba T
    Nihon Rinsho; 2004 May; 62 Suppl 5():364-7. PubMed ID: 15197946
    [No Abstract]   [Full Text] [Related]  

  • 22. Vitamin D analogs as therapeutic agents: a clinical study update.
    Wu-Wong JR; Tian J; Goltzman D
    Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease.
    Wolf M; Thadhani R
    Semin Dial; 2005; 18(4):302-6. PubMed ID: 16076353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis.
    Duranton F; Rodriguez-Ortiz ME; Duny Y; Rodriguez M; Daurès JP; Argilés A
    Am J Nephrol; 2013; 37(3):239-48. PubMed ID: 23467111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 26. [Paracalcitiol compared with calcitriol in treatment of secondary hyperparathyroidism in patients with hemodyalisis. Are they really different?].
    Peña-Rodriguez JC
    Rev Invest Clin; 2004; 56(1):8-10. PubMed ID: 15144035
    [No Abstract]   [Full Text] [Related]  

  • 27. Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
    Stubbs JR; Wetmore JB
    Semin Dial; 2011; 24(3):298-306. PubMed ID: 21682772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of 1,25-dihydroxyvitamin D3 in early renal failure.
    Goodman WG; Coburn JW
    Annu Rev Med; 1992; 43():227-37. PubMed ID: 1580587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3].
    Ohtsuka N; Urayama K
    Nihon Yakurigaku Zasshi; 2002 Dec; 120(6):427-36. PubMed ID: 12528474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent progress in management of secondary hyperparathyroidism of chronic renal failure.
    Akizawa T; Fukagawa M; Koshikawa S; Kurokawa K
    Curr Opin Nephrol Hypertens; 1993 Jul; 2(4):558-65. PubMed ID: 7859018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Abnormalities in parathyroid hormone and calcitonin associated with uremia].
    Okazaki R
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():169-72. PubMed ID: 15250289
    [No Abstract]   [Full Text] [Related]  

  • 32. 1,25 (OH)2 vitamin D3 deficiency and renal osteodystrophy: should its well-accepted pathogenetic role in secondary hyperparathyroidism lead to its systematic preventive therapeutic use?
    Fournier A; Moriniere P; Boudaillez B; Renaud H; Marie A; Westeel PF; Hocine C; Belbrik S
    Nephrol Dial Transplant; 1987; 2(6):498-503. PubMed ID: 3126450
    [No Abstract]   [Full Text] [Related]  

  • 33. Intermittent calcitriol therapy and growth in children with chronic renal failure.
    Kuizon BD; Salusky IB
    Miner Electrolyte Metab; 1998; 24(4):290-5. PubMed ID: 9554570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical uses of 22-oxacalcitriol.
    Mizobuchi M; Ogata H
    Curr Vasc Pharmacol; 2014 Mar; 12(2):324-8. PubMed ID: 23713875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Considerations for the treatment of secondary hyperparathyroidism in renal failure.
    Felsenfeld AJ
    J Am Soc Nephrol; 1997 Jun; 8(6):993-1004. PubMed ID: 9189868
    [No Abstract]   [Full Text] [Related]  

  • 36. Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure.
    Llach F; Yudd M
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S3-12. PubMed ID: 9808139
    [No Abstract]   [Full Text] [Related]  

  • 37. Pathogenesis of secondary hyperparathyroidism.
    Drüeke T
    Kidney Blood Press Res; 1997; 20(3):154-6. PubMed ID: 9293429
    [No Abstract]   [Full Text] [Related]  

  • 38. Vitamin D receptor activators.
    Mazzaferro S; Pasquali M; Conte C; Mandanici G; Muci M; Lavini R
    Int J Artif Organs; 2009 Feb; 32(2):101-7. PubMed ID: 19363782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure.
    Llach F; Yudd M
    Nephrol Dial Transplant; 1998; 13 Suppl 3():57-61. PubMed ID: 9568822
    [No Abstract]   [Full Text] [Related]  

  • 40. Cardiovascular disease in patients on chronic hemodialytic therapy.
    Scharf S; Wexler J; Longnecker RE; Blaufox MD
    Prog Cardiovasc Dis; 1980; 22(5):343-56. PubMed ID: 6987711
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.